Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Our primary focus is the development of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Mucopolysaccharidosis Type IIIB (Sanfilippo syndrome Type B).